These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38936819)

  • 21. Selective blockade of the 5-HT
    Kwan C; Nuara SG; Bédard D; Gaudette F; Gourdon JC; Beaudry F; Huot P
    Neuropharmacology; 2021 Jan; 182():108386. PubMed ID: 33152452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The highly selective 5-HT
    Hamadjida A; Nuara SG; Bédard D; Gaudette F; Beaudry F; Gourdon JC; Huot P
    Neuropharmacology; 2018 Sep; 139():61-67. PubMed ID: 29969592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
    Hamadjida A; Nuara SG; Bédard D; Frouni I; Kwan C; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Dec; 391(12):1339-1345. PubMed ID: 30088028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 5-HT
    Kwan C; Frouni I; Bédard D; Hamadjida A; Nuara SG; Gourdon JC; Huot P
    Eur J Neurosci; 2024 Mar; 59(6):1169-1176. PubMed ID: 37515363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
    Hamadjida A; Nuara SG; Gourdon JC; Huot P
    J Neural Transm (Vienna); 2018 Sep; 125(9):1355-1360. PubMed ID: 29247391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
    Beaudry F; Huot P
    J Neural Transm (Vienna); 2020 Oct; 127(10):1343-1358. PubMed ID: 32860561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
    Hamadjida A; Nuara SG; Veyres N; Frouni I; Kwan C; Sid-Otmane L; Harraka MJ; Gourdon JC; Huot P
    Psychopharmacology (Berl); 2017 Mar; 234(6):905-911. PubMed ID: 28130646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Jenner P
    Mov Disord; 2001 Jul; 16(4):631-41. PubMed ID: 11481686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
    Frouni I; Kang W; Bédard D; Belliveau S; Kwan C; Hadj-Youssef S; Bourgeois-Cayer É; Ohlund L; Sleno L; Hamadjida A; Huot P
    Eur J Pharmacol; 2022 Aug; 929():175090. PubMed ID: 35780824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Charvin D; Di Paolo T; Bezard E; Gregoire L; Takano A; Duvey G; Pioli E; Halldin C; Medori R; Conquet F
    Mov Disord; 2018 Oct; 33(10):1619-1631. PubMed ID: 30216534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
    Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
    Huot P; Johnston TH; Fox SH; Newman-Tancredi A; Brotchie JM
    Neuropharmacology; 2015 Oct; 97():306-11. PubMed ID: 26071982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
    Mann E; Jackson M; Lincoln L; Fisher R; Rose S; Duty S
    J Parkinsons Dis; 2020; 10(3):959-967. PubMed ID: 32250315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
    Hadj Tahar A; Ekesbo A; Grégoire L; Bangassoro E; Svensson KA; Tedroff J; Bédard PJ
    Eur J Pharmacol; 2001 Feb; 412(3):247-54. PubMed ID: 11166288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.